FindTrial
Sign In

Length of nasogastric tube(Ryles tube) will be increased by 10 cm during insertion in patients with acute poisoning for evacuation of poison.

A randomized control trial to assess the safety of "Modified nasogastric tube length insertion" on selected outcome variables-amongst the patients with acute poison ingestion, admitted in EMOPD, PGIMER, in Chandigarh, 2018-20.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/018914
Enrollment
80
Registered
2019-05-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: T600- Toxic effect of organophosphate and carbamate insecticides Health Condition 2: T600- Toxic effect of organophosphate and carbamate insecticides

Interventions

Intervention1: Modified nasogastric length insertion: Length of nasogastric tube will be increased by 10 cm from the standard length measurement by NEX method and aspiration and lavage will be done to

Sponsors

PGIMER Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with acute poison ingestion, admitted in EMOPD, PGIMER, Chandigarh within 6 hours of poison consumption. 2. Patients without any contraindication for Ryleâ??s tube insertion (Contraindications include deviated nasal septum, cancer of oral cavity or throat, nasal polyps, nasal injury, nasal surgery etc.) 3. Patients /attendants willing to give consent. 4. Patients above 18 years of age. 5. In case of comatose patients gastric lavage will be done only after airway protection.

Exclusion criteria

Exclusion criteria: 1. Patients referred for further treatment after initial lavage from outside the PGIMER, Chandigarh. 2. Patients with Corrosive and hydrocarbons poisoning/ Volatile substance.

Design outcomes

Primary

MeasureTime frame
1.Incidence of aspiration pneumonia. 2.Hemodynamic safety. Timepoint: 7 Months—

Secondary

MeasureTime frame
1. Duration and dose of atropinization. 2. Complications (Respiratory failure, intermediate syndrome, duration of mechanical ventilation). 3. Duration of hospital stay. 4. In- hospital mortality. Timepoint: 7 months—

Countries

India

Contacts

Public ContactDr Sukhpal Kaur

NINE PGIMER Chandigarh

anjalisharma.ansh26@gmail.com08901460537

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026